The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Jeffrey Del Carmen net worth and biography

Jeffrey Del Carmen Biography and Net Worth

EVP, Chief Commercial Officer of Catalyst Pharmaceuticals

Jeff Del Carmen joined Catalyst in August 2018 as Senior Vice President of Sales and Marketing and was promoted to Chief Commercial Officer in June 2020. Mr. Del Carmen brings over 22 years of pharmaceutical experience to Catalyst, including numerous commercial leadership positions in the neurology orphan disease space. Most recently, Mr. Del Carmen served as VP of Business Development at Paragon Biosciences where he focused on business development for orphan neurology diseases. Prior to joining Paragon, he was Senior Director-Rare Disease Marketing at Marathon Pharmaceuticals. Previously, Mr. Del Carmen served as VP of Sales at Insys Therapeutics from January 2016 to July 2016, as well as National Sales Director of Movement Disorders and Regional Business Director of Neurology at Lundbeck. He also held numerous sales and marketing positions of increasing responsibility at Abbott Laboratories. Mr. Del Carmen holds a B.A. in Economics from the University of Dayton and an Executive MBA from the University of Wisconsin-Madison.

What is Jeffrey Del Carmen's net worth?: The estimated net worth of Jeffrey Del Carmen is at least $263,088.63 as of August 9th, 2024. Mr. Del Carmen owns 12,369 shares of Catalyst Pharmaceuticals stock worth more than $263,089 as of December 22nd. This net worth evaluation does not reflect any other investments that Mr. Del Carmen may own. Additionally, Mr. Del Carmen receives a salary of $799,820.00 as EVP, Chief Commercial Officer at Catalyst Pharmaceuticals. Learn More about Jeffrey Del Carmen's net worth.
How old is Jeffrey Del Carmen?: Mr. Del Carmen is currently 53 years old. There are 5 older executives and no younger executives at Catalyst Pharmaceuticals. The oldest executive at Catalyst Pharmaceuticals is Dr. Gary Ingenito M.D., Ph.D., Chief Medical & Regulatory Officer, who is 68 years old. Learn More on Jeffrey Del Carmen's age.
What is Jeffrey Del Carmen's salary?: As the EVP, Chief Commercial Officer of Catalyst Pharmaceuticals, Inc., Mr. Del Carmen earns $799,820.00 per year. There are 2 executives that earn more than Mr. Del Carmen. The highest earning executive at Catalyst Pharmaceuticals is Dr. Steven R. Miller Ph.D., Executive VP, COO & Chief Scientific Officer, who commands a salary of $884,700.00 per year. Learn More on Jeffrey Del Carmen's salary.
How do I contact Jeffrey Del Carmen?: The corporate mailing address for Mr. Del Carmen and other Catalyst Pharmaceuticals executives is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. Catalyst Pharmaceuticals can also be reached via phone at (305) 420-3200 and via email at [email protected]. Learn More on Jeffrey Del Carmen's contact information.
Has Jeffrey Del Carmen been buying or selling shares of Catalyst Pharmaceuticals?: Jeffrey Del Carmen has not been actively trading shares of Catalyst Pharmaceuticals during the last ninety days. Most recently, Carmen Jeffrey Del sold 36,058 shares of the business's stock in a transaction on Friday, August 9th. The shares were sold at an average price of $18.42, for a transaction totalling $664,188.36. Following the completion of the sale, the insider now directly owns 12,369 shares of the company's stock, valued at $227,836.98. Learn More on Jeffrey Del Carmen's trading history.
Who are Catalyst Pharmaceuticals' active insiders?: Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 440,755 shares worth more than $8,352,888.44. The most recent insider tranaction occured on December, 10th when insider Steve Miller sold 50,000 shares worth more than $1,096,500.00. Insiders at Catalyst Pharmaceuticals own 11.0% of the company. Learn More about insider trades at Catalyst Pharmaceuticals.
Information on this page was last updated on 12/10/2024.

Jeffrey Del Carmen Insider Trading History at Catalyst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/9/2024	Sell	36,058	$18.42	$664,188.36	12,369
6/7/2024	Sell	7,541	$16.07	$121,183.87	18,427
3/29/2023	Sell	40,000	$16.70	$668,000.00	7,541

Jeffrey Del Carmen Buying and Selling Activity at Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Company Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $21.27

$21.01

$21.41

50 Day Range

MA: $21.77

$20.60

$23.93

2 Week Range

Now: $21.27

$13.12

$24.27

Volume

1,753,179 shs

Average Volume

1,169,952 shs

Market Capitalization

$2.54 billion

P/E Ratio

18.03

Dividend Yield

N/A

Beta

0.75

Vladimir Lenin was right…

From Porter & Company | Ad

Including the name of the #1 company to buy.

Jeffrey Del Carmen Biography and Net Worth

What is Jeffrey Del Carmen's net worth?

How old is Jeffrey Del Carmen?

What is Jeffrey Del Carmen's salary?

How do I contact Jeffrey Del Carmen?

Has Jeffrey Del Carmen been buying or selling shares of Catalyst Pharmaceuticals?

Who are Catalyst Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Catalyst Pharmaceuticals?